The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron’s proposal to add additional ...

Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Another complete response letter from the U.S. FDA for Regeneron Pharmaceuticals Inc.’s age-related macular degeneration (AMD) therapy Eylea (aflibercept) – along with disappointing sales of the VEGF ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s ...